Global Kidney Fibrosis Treatment Market Predicted To Advance At A CAGR Of About 4.8% During 2024-2032

As per researchers at Zion Market Research, the global Kidney Fibrosis Treatment Market was valued at USD 4.78 Billion in 2023 and is projected to hit USD 7.65 Billion by 2032, with a compound annual growth rate (CAGR) of 4.8% during the forecast period 2024-2032. Fibrosis is the body process wherein the extra fibrous connective tissue is structured in the tissue or organ in a repetitive way. Fibrosis might be caused by precise diseases or injuries. Kidney fibrosis is an ordinary pathway for the CKD (chronic kidney disease) or ESRD (end-stage kidney diseases). Kidney fibrosis is caused resulted owing to the excess formation of the extracellular matrix—a normal phenomenon caused by each kind of CKD. At present, the kidney fibrosis market is experiencing rewarding growth due to the increasing prevalence of CKDs and renal fibrosis. The surging patient base is expected to promote the development of this market in the future.

Some of the prominent players in the market are F. Hoffman-La Roche Ltd.; Merck & Co.; Galectin Therapeutics; Pfizer Inc.; InterMune Inc.; La Jolla Pharmaceutical Company; Genzyme Corporation; ProMetic Life-Sciences Inc.; and BioLine Rx Ltd.

Augmented Prevalence Of CKD To Accelerate The Expansion Of Global Kidney Fibrosis Treatment Market

The global kidney fibrosis treatment market is anticipated to witness growth during the forecasted period, due to the augmented prevalence of CKD. The altering lifestyle along with a change in food habits is the main reason for the surging base of kidney disease patients and is likely to advance the market for kidney fibrosis treatment. In addition, aspects like increasing geriatric population base globally, mounting disposable earnings of the patients, and raising consciousness about renal fibrosis treatment are key growth factors of this market over the estimated period. The continuous modernization in technology has resulted in the development of effective & safe therapies for the treatment of CKD. The introduction of the potential drug in the market with positive government initiative is estimated to boost the market growth due to the increasing survival rate and efficiency of these medicines in renal patients. The developing nations like China and India possess noteworthy growth opportunities for kidney fibrosis treatment market due to surging medical expenditure and increasing medical tourism rates.

The global kidney fibrosis treatment market is bifurcated on the basis of location of testing, therapeutics, and regional analysis. Based on the therapeutics, the market is divided into ARBs (angiotensin II receptor blockers), ACE (angiotensin converting enzyme) inhibitors, renin inhibitors, pirfenidone, and vasopeptidase inhibitors. Based on the location of testing, the market is divided into commercial/private hospitals, hospital testing, clinics, public health hospitals, and home treatment.

The North America Region Will Witness Massive Growth In The Global Kidney Fibrosis Treatment Market

Based on geographical analysis, the global kidney fibrosis treatment market is divided into North America, Europe, Latin America, Asia Pacific, and Middle East & Africa. The North America region dominated the global kidney fibrosis treatment market during 2014 in terms of market revenue. Owing to the large patient base of CKD, this region is expected to show a noteworthy growth rate during the estimated period. The introduction of treatment for end-stage kidney therapeutics across the U.S. since 2011 is a major growth driver for this market.

Browse the full “Kidney Fibrosis Treatment Market - By Therapeutics (Angiotensin II Receptor Blockers, Angiotensin Converting Enzyme Inhibitors, Renin Inhibitors, Pirfenidone, And Vasopeptidase Inhibitors), By Location Of Testing (Commercial/Private Hospitals, Hospital Testing, Clinics, Public Health Hospitals, And Home Treatment), And By Region - Global Industry Perspective, Comprehensive Analysis, And Forecast, 2024-2032.” Report at https://www.zionmarketresearch.com/report/kidney-fibrosis-treatment-market

The global kidney fibrosis treatment market is segmented as follows:

By therapeutics:

• Angiotensin II receptor blockers (ARBs)
• Angiotensin Converting Enzyme (ACE) inhibitors
• Pirfenidone
• Renin Inhibitors
• Vasopeptidase Inhibitors

By location of testing:

• Public health hospitals
• Hospital testing
• Commercial/private hospitals
• Clinics
• Home Treatment

By region:

• North America
  • The U.S.
  • Canada
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com